Table 3. NCI-CTC all grade toxicities.
|
ECX+matuzumab 400 mg weekly N=7
|
ECX+matuzumab 800 mg weekly N=7
|
ECX+matuzumab 1200 mg every 3 weeks N=7
|
Adverse events
|
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NCI-CTC grade | NCI-CTC grade | NCI-CTC grade | Total | (%) | ||||||||||
| Toxicity | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | 1 | 2 | 3 | 4 | ||
| Rash | 1 | 2 | 0 | 0 | 4 | 0 | 1 | 0 | 2 | 3 | 0 | 0 | 13 | 61.9 |
| Headache | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 4.8 |
| Diarrhoea | 5 | 0 | 0 | 0 | 3 | 1 | 0 | 0 | 2 | 1 | 2 | 0 | 14 | 66.7 |
| Abdo pain | 1 | 1 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 1 | 2 | 0 | 8 | 38 |
| PPE | 0 | 1 | 2 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 6 | 28.6 |
| Stomatitis | 3 | 2 | 0 | 0 | 2 | 2 | 0 | 0 | 5 | 1 | 0 | 1 | 16 | 76.2 |
| Nausea | 3 | 2 | 1 | 0 | 2 | 1 | 0 | 0 | 2 | 2 | 3 | 0 | 16 | 76 |
| Vomiting | 3 | 2 | 1 | 0 | 0 | 0 | 1 | 0 | 2 | 4 | 1 | 0 | 14 | 66.7 |
| Lethargy | 1 | 1 | 0 | 1 | 2 | 1 | 2 | 1 | 0 | 1 | 6Ψ | 0 | 16 | 76 |
| Neutropaenia | 0 | 0 | 1 | 0 | 3 | 1 | 1 | 2 | 4 | 12 | 57 | |||
| Febrile neutropaenia | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 4.8 |
| Thrombocytopaenia | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 4.8 |
ECX=epirubicin, cisplatin and capecitabine; NCI-CTC=National Cancer Institute Common Toxicity Criteria; Ψ=Main DLT.